Meta-analysis of 6377 cases with primary BC administered with neoadjuvant anthracycline-taxane in 7 randomized studies revealed pCR as a valid substitute of DFS and OS in HER2+ subtypes [37]. The gene discussed is ERBB2; the disease is breast cancer.